Activated mesenchymal stem cells for treating limb ischemia

Abstract

A method for treating limb ischemia in a patient in need of such treatment by administering metamizole treated mesenchymal stem cells to the patient. The method provides a pharmaceutical product for angiogenesis growth to replace occluded blood vessels for avoiding limb amputation. Secretion of angiogenic growth factors VEGFA, HGF, bFGF, TEK are stimulated and the levels of pro-inflammatory cytokines IF6, CXCF8, CCF2, IL1-RN are reduced by activation of mesenchymal stem cells (MSCs). According to treatment results, MSCs produce proteins and signaling molecules for new blood vessel growth that accelerate the growth of new arteries.

Dependencies are inferred from the claim text.